CORDIS
EU research results

CORDIS

English EN

ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer

Objective

This ETN is embedded into an established international research programme; The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA; www.erialcl.net) is an existing and functional network of 13 partners, which will cosset and nurture a cohort of early stage researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives. ERIA was instigated to coordinate research into ALK-related malignancies to facilitate the development of less-toxic and more efficacious therapies. ALK is increasingly recognised as a prevalent oncogene in a number of human malignancies and therefore poses a prominent clinical problem, which requires coordinated research into its oncogenic mechanisms. ERIA now conducts a collaborative multidisciplinary research programme at the interface of biomedical and bio-mechanistic approaches, which will be an excellent environment to train the next generation of European scientists. The 15 recruited fellows will be incorporated into international academic study groups (all partners of the ERIA network) to perform high calibre research and also will be exposed to environments from other sectors to broaden their experience. Secondments will include technical training within individual laboratories and SMEs (TissueGnostics, Galkem, Cambridge Life Sciences, Sofigen and Varionostics) as well as large Pharma (Roche). Training through research will be complemented with a balanced programme of transferable skills and access to local courses. The training of each fellow will be guided by a personal career development plan and supervised by a PhD committee panel. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into an international network. Thereby providing competence in state-of-the-art research and development at the forefront of translational science.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Address

Trinity Lane The Old Schools
Cb2 1tn Cambridge

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 546 575,76

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 574 216,55

LUDWIG BOLTZMANN GESELLSCHAFT GMBH

Austria

EU Contribution

€ 193 585,69

Masarykova univerzita

Czechia

EU Contribution

€ 232 422,48

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 249 216,48

UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA

Italy

EU Contribution

€ 258 061,32

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 525 751,20

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 249 216,48

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 258 061,32

JUSTUS-LIEBIG-UNIVERSITAET GIESSEN

Germany

EU Contribution

€ 249 216,48

INSTITUT GUSTAVE ROUSSY

France

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 263 659,32

UNIVERSITAETSKLINIKUM FREIBURG

Germany

EU Contribution

€ 249 216,48

Partners (10)

Sort alphabetically

Expand all

The Naked Scientists

TISSUEGNOSTICS GMBH

Roche Austria

GALKEM SRL

BIOLUTION GMBH

VARIONOSTIC GMBH

Central European Society of Anti-Cancer Research (CESAR)

MEDIZINISCHE UNIVERSITAT GRAZ

Cambridge Life sciences

Sofigen

Project information

Grant agreement ID: 675712

Status

Ongoing project

  • Start date

    1 September 2015

  • End date

    31 August 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 849 199,56

  • EU contribution

    € 3 849 199,56

Coordinated by:

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom